12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Victrelis boceprevir: Additional Phase III data

Additional data from the double-blind, international Phase III HCV RESPOND-2 trial in 403 patients with chronic HCV genotype 1 infection who failed prior therapy with peginterferon and ribavirin showed that 88% (n=84) and 86% (n=74) of patients with undetectable HCV RNA levels at week 8 in the 48-week and response-guided Victrelis plus PegIntron peginterferon alfa-2b and Rebetol ribavirin treatment groups, respectively, achieved an SVR. Additionally, a smaller proportion of patients in the 48-week and response-guided treatment groups relapsed vs. placebo plus PegIntron and Rebetol (12% and 15%, respectively, vs. 32%).

Furthermore, a significantly greater proportion of Victrelis-treated patients in the 48-week...

Read the full 506 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >